Jazz Pharmaceuticals, Inc. (JAZZ) — Analysis Summary
Jazz Pharmaceuticals, Inc. (JAZZ) has a market cap of $14.89B with year-over-year revenue growth of +4.9%. Net margin stands at -8.3%. The stock trades at a P/E ratio of 504.7.
Key Takeaways
- Revenue changed +4.9% year-over-year
- Net margin of -8.3%
- P/E ratio of 504.7
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, JAZZ posted revenue growth of +4.9% and trades at a P/E of 504.7.
Jazz Pharmaceuticals, Inc. (JAZZ)
UPDATED — ET · SOURCE POLYGON
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Debt/EBITDA at 2119.0x — highly leveraged, potential refinancing risk
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Sector
PHARMACEUTICAL PREPARATIONS
Employees
2,890
Headquarters
DUBLIN
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.